Drugs / L218CAR19
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06478381 | Jun 2024 → Dec 2025 | B-cell non-Hodgkin lymphoma | Henan Cancer Hospital | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | L218CAR19 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06478381 ↗ |
| Modality | Cell therapy | “L218CAR19 is a kind of chimeric antigen receptor T-cell immunotherapy targeting CD19 on B cells.” NCT06478381 ↗ |
| Route | Intravenous | “L218CAR19 is intravenously administered at three dose levels.” NCT06478381 ↗ |
| Target | CD19 | “targeting CD19 on B cells” NCT06478381 ↗ |